Immunodominance deters the response to other tumor antigens thereby favoring escape: Prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro

Tissue Antigens

Volumn 47, Issue 5, 1996, Pages 399-407

  Van Waes, C ^a   Monach, P A ^a   Urban, J L ^a   Wortzel, R D ^a   Schreiber, H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Active vaccination; Cancer recurrence; Immunodominance; Prevention; Tumor escape; Tumor variant

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER MODEL; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

ANIMALIA; MURINAE;

EID: 0029888140     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02575.x     Document Type: Article

References (33)

1. Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989: 170: 217-32.
2. + T-cell-dependent surveillance. Cancer Res 1990: 50: 3851-8.
3. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H. Mechanisms of syngeneic tumor rejection: susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 1982: 155: 557-73.
4. Van Waes C, Urban JL, Rothstein JL, Ward PL, Schreiber H. Highly malignant tumor variants retain tumor-specific antigens recognized by helper T cells. J Exp Med 1986: 164: 1547-65.
5. + T cells to an antigen that no longer serves as a target. J Exp Med 1993: 178: 933-40.
6. Garrido F, Cabrera T, Concha, A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Todav 1993: 14: 491-9.
7. Wortzel RD, Philipps C, Urban JL, Fitch FW, Schreiber H. Independent immunodominant and immunorecessive tumor-specific determinants on a malignant tumor. Antigenic dissection with cytolytic T cell clones. J Immunol 1983: 130: 2461-6.
8. Wortzel RD, Philipps C, Schreiber H. Multiplicity of unique tumor-specific antigens expressed on a single malignant cell. Nature 1983: 304: 165-7.
9. Wortzel RD, Urban JL, Schreiber H. Malignant growth in the normal host after variant selection in vitro with cytolytic T cell lines. Proc Natl Acad Sci U S A 1984: 81: 2186-90.
10. Fisher MS, Kripke ML. Systemic alteration induced by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci U S A 1977: 74: 1688-92.
11. + lymphocytes. Transplantation 1993: 55: 1349-55.
12. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974: 53: 1333-6.
13. Kripke ML. Latency, histology and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 1977: 37: 1395-1400.
14. Philipps C, McMillan M, Flood PM et al. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci U S A 1985: 82: 5140-4.
15. Stauss HJ, Van Waes C, Fink MA, Starr B, Schreiber H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med 1986: 164: 1516-30.
16. Linsk R, Watts S, Fischer A, Goodenow RS. The tumor-rejection antigens of the 1591 ultraviolet fibrosarcoma. J Exp Med 1989: 169: 1043-58.
17. d, and two genes reported to encode tumor-specific antigens. J Exp Med 1988: 168: 1719-39.
18. Urban JL, Holland MJ, Kripke ML, Schreiber H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med 1982: 156: 1025-41.
19. Urban JL, Van Waes C, Schreiber H. Pecking order among tumor-specific antigens. Eur J Immunol 1984: 14: 181-7.
20. Rowley DA, Stach RM. A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens. J Exp Med 1993: 178: 835-40.
21. Stach RM, Rowley DA. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor β and suppresses cytolytic T cell responses to unrelated alloantigens. J Exp Med 1993: 178: 841-52.
22. Urban JL, Kripke ML, Schreiber H. Stepwise immunological selection of antigenic variants during tumor growth. J Immunol 1986: 137: 3036-41.
23. Knuth A, Wölfel T, Klehmann E, Boon T, Meyer zum Buschenfelde K-H. Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A 1989: 86: 2804-8.
24. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC Class I-restricted tumor antigens. Science 1994: 264: 961-5.
25. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990: 171: 377-87.
26. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990: 249: 918-21.
27. Bianchi ATJ, Bril H, Brenner R. Alloantigen-specific suppressor T cells can also suppress the in vivo immune response to unrelated alloantigens. Nature 1983: 301: 614-16.
28. Kaliss N, Snell GD. The effects of injections of lyophilized normal and neoplastic mouse tissues on the growth of tumor homoiotransplants in mice. Cancer Res 1951: 11: 122-6.
29. Snell GD. Enhancement and inhibition of the growth of tumor homoiotransplants by pretreatment of the hosts with various preparations of normal and tumor tissue. J Natl Cancer Inst 1952: 13: 719-29.
30. Kandutsch AA, Reinert-Wenck R. Studies on a substance that promotes homograft survival (the "enhancing substance") its distribution and some properties. J Exp Med 1957: 105: 125-39.
31. Vaage J. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue. Cancer Res 1971: 31: 1655-62.
32. Gershon RK, Mokyr MB, Mitchell MS. Activation of suppressor T cells by tumor cells and specific antibody. Nature 1974: 250: 594-6.
33. Schreiber H. Tumor immunology. In: Paul W, ed. Fundamental immunology. 3rd edn. New York: Raven Press, 1993: 1143-78.